Chapter 22: Problem 22
Private companies are now offering personal DNA sequencing along with interpretation. What services do they offer? Do you think that these services should be regulated, and if so, in what way?
Chapter 22: Problem 22
Private companies are now offering personal DNA sequencing along with interpretation. What services do they offer? Do you think that these services should be regulated, and if so, in what way?
All the tools & learning materials you need for study success - in one app.
Get started for free(a) Would you agree with Judge Sweet's ruling to invalidate the patenting of the \(B R C A 1\) and \(B R C A 2\) genes? If you were asked to judge the patenting of the direct-to-consumer test for the \(B R C A 1\) and \(B R C A 2\) genes, how would you rule? (b) \(\mathrm{J}\). Craig Venter has filed a patent application for his "firstever human made life form." This patent is designed to cover the genome of \(M .\) genitalium. Would your ruling for Venter's "organism" be different from Judge Sweet's ruling on patenting of the \(B R C A 1\) and \(B R C A 2\) genes?
What is the main purpose of genome-wide association studies (GWAS)? How can information from GWAS be used to inform scientists and physicians about genetic diseases?
There are more than 1000 cloned farm animals in the United States. In the near future, milk from cloned cows and their offspring (born naturally) may be available in supermarkets. These cloned animals have not been transgenically modified, and they are no different than identical twins. Should milk from such animals and their natural-born offspring be labeled as coming from cloned cows or their descendants? Why?
The first attempts at gene therapy began in 1990 with the treatment of a young girl with a genetic disorder abbreviated SCID. What does SCID stand for? In the context of SCID, what does ADA stand for?
Dominant mutations can be categorized according to whether they increase or decrease the overall activity of a gene or gene product. Although a loss-of- function mutation (a mutation that inactivates the gene product) is usually recessive, for some genes, one dose of the normal gene product, encoded by the normal allele, is not sufficient to produce a normal phenotype. In this case, a loss-of-function mutation in the gene will be dominant, and the gene is said to be haploinsufficient. A second category of dominant mutation is the gain- of-function mutation, which results in a new activity or increased activity or expression of a gene or gene product. The gene therapy technique currently used in clinical trials involves the "addition" to somatic cells of a normal copy of a gene. In other words, a normal copy of the gene is inserted into the genome of the mutant somatic cell, but the mutated copy of the gene is not removed or replaced. Will this strategy work for either of the two aforementioned types of dominant mutations?
What do you think about this solution?
We value your feedback to improve our textbook solutions.